Core Viewpoint - Xiaomi is trialing humanoid robots in its electric vehicle production plants to enhance productivity, with the potential for these robots to replace certain human tasks in the future [1][4]. Group 1: Humanoid Robots in Production - Two humanoid robots can complete 90% of the work in three hours, performing tasks such as installing nuts and moving materials [2]. - The integration of robots into production lines faces challenges, particularly in maintaining the pace of assembly, where a new car is produced every 76 seconds [2]. - Currently, the use of robots in Xiaomi's production lines is in early stages, functioning more like interns rather than performing official jobs [5]. Group 2: Market Potential and Industry Trends - The global total addressable market for humanoid robots is projected to reach $9 trillion by 2050, with China expected to account for over 60% of this market [6]. - Other Chinese companies, such as XPeng and Honor, are also developing humanoid robots, indicating a broader trend in the industry [7]. - Xiaomi's president expressed optimism about the robotics sector but noted it is too early to determine the market size [7].

Core Insights - Quantum-Si is focusing on the development and commercial readiness of its Proteus platform, with an expected launch at the end of 2026, which will impact near-term revenue [4][6][19] Financial Performance - For the full year 2025, Quantum-Si reported revenue of $2.4 million, with a gross profit of $1.2 million and a gross margin of 47% [15] - The company ended 2025 with $215.8 million in cash and equivalents, and for 2026, it projects approximately $1 million in revenue, with adjusted operating expenses capped at $98 million and cash usage at $93 million [5][18][19] Strategic Initiatives - The company has expanded its instrument acquisition options, securing 17 new customers across academic labs, pharma, and biotech, which helps in accessing key opinion leaders [2][6] - Quantum-Si is building a publication pipeline to demonstrate broader applications of its technology, with five manuscripts submitted in 2025 and three new releases in early 2026 [1][6] Product Development - The Proteus platform is expected to launch with a list price of $425,000, and the company is currently focusing on direct capital purchases for this product [8][10] - The company has made progress in its prototype systems, with successful internal deployments for R&D and plans for further manufacturing and delivery of additional instruments [11] Market Positioning - Quantum-Si is targeting higher consumable utilization rates and repeat ordering patterns through new applications in clinical proteomics and rapid pathogen detection [7][6] - The company is also exploring partnership opportunities to enhance its offerings, including artificial intelligence tools for deeper insights from protein sequencing data [7]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has successfully secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][11] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [11][78] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [24][26] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [23][25] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [27] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt it based on its capabilities [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions [45][47] Question: What applications are expected to provide a tailwind for Proteus? - Management highlighted the potential for Proteus in complex biological samples and post-translational modifications, which are key areas of focus [64][66] Question: Will there be an increase in the field sales force for Proteus? - Management confirmed that the total spend for 2026 includes augmenting the commercial team to be launch-ready for Proteus [67][68]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][10] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as its corporate priorities for 2025 [4][18] - The focus for 2026 is on developing the market for Proteus, with a deliberate strategy to prioritize long-term platform adoption over short-term revenue maximization [24][26] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, with expectations of limited capital sales and a focus on consumable revenue [5][24] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The list price for Proteus has been set at $425,000, aimed at balancing premium value with accessibility for potential customers [11][78] - The company has a strong balance sheet with $215.8 million in cash and investments, allowing for strategic execution into 2028 [23][25] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted a consistent purchase rate from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt at varying rates based on application availability and financial incentives [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions with potential customers [45][46] Question: Will Proteus be available through leasing or rental options? - Currently, the company plans to launch Proteus with direct capital sales only, with potential for other acquisition models to be evaluated based on market feedback [81]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, while full-year operating expenses were $117.3 million, compared to $110.2 million in 2024 [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [31] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][12] - The NIH funding environment is showing signs of improvement, which may positively impact customer capital spending [50] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [12][80] Management Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [25][27] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][28] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [24][26] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [28] Q&A Session Summary Question: What are the trends in consumables within the installed base? - The company is seeing consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [30][31] Question: Should we expect very few placements in 2026, with most revenue from consumables? - Yes, the revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [33][34] Question: Can you discuss the launch curve for Proteus? - The launch will likely follow an S-curve, with existing Platinum users transitioning to Proteus and new customers being engaged [36][39] Question: Does the $98 million in guidance for operating expenses include stock compensation? - The adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [42] Question: Is the price point for Proteus based on secured pre-orders? - No secured orders are in place; the price is released to assist customers in their capital planning [46][47] Question: Will there be a rental program for Proteus? - Currently, only direct capital sales have been announced, with potential for other acquisition models to be evaluated based on market feedback [83]

Quantum-Si, Inc. (NASDAQ:QSI) shares moved lower in Tuesday's extended trading after the company released its fourth-quarter earnings report, missing Street revenue estimates. Here's a look at the key figures from the quarter. QSI stock is moving. Watch the price action here.The Details: Quantum-Si reported quarterly loss of 8 cents per share, which beat the Street estimate for a loss of 12 cents, according to Benzinga Pro.Quarterly revenue came in at $451,000, which missed the $762,000 analyst estimate.The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Table of Contents or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______to______ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in it ...

Financial Performance - For Q4 2025, Quantum-Si reported revenue of $0.5 million, with a gross profit of $0.1 million and a gross margin of 27%[4] - For the full year 2025, total revenue was $2.4 million, gross profit was $1.2 million, and gross margin was 47%[4] - The net loss for Q4 2025 was $17.6 million, an improvement from a net loss of $33.1 million in Q4 2024, with a full year net loss of $101.3 million compared to $101.0 million in the prior year[7] - Total revenue for Q4 2025 was $451 million, a decrease of 62% compared to $1,192 million in Q4 2024[24] - Gross profit for the year ended December 31, 2025, was $1,153 million, down from $1,600 million in 2024, reflecting a gross margin decline[24] - Net loss for Q4 2025 was $17,611 million, compared to a net loss of $33,121 million in Q4 2024, indicating an improvement in financial performance[27] - Adjusted EBITDA for the year ended December 31, 2025, was $(80,731) million, compared to $(92,836) million in 2024, showing a narrowing loss[27] - Total comprehensive loss for Q4 2025 was $17,671 million, compared to $33,229 million in Q4 2024, reflecting a significant reduction in overall losses[24] Operating Expenses - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, while full year operating expenses were $117.3 million compared to $110.2 million in 2024[5][6] - Adjusted total operating expenses for 2026 are projected to be $98.0 million or less, with total cash usage expected to be $93.0 million or less[9] - One-time charges related to legacy litigation matters totaled $18.7 million for the year ended December 31, 2025[8] - Research and development expenses for the year ended December 31, 2025, totaled $53,759 million, down from $59,641 million in 2024[24] Cash and Liquidity - As of December 31, 2025, Quantum-Si had cash and cash equivalents totaling $215.8 million, providing sufficient runway to support operations into Q2 2028[11] Strategic Initiatives - Quantum-Si announced a list price of $425,000 for the Proteus platform, aimed at capturing premium value while being accessible to more customers[3] - The company expects 2026 revenue to be approximately $1.0 million, impacted by strategic actions taken ahead of the Proteus launch[9] - The company is embedding upgrade credits into Platinum Pro units sold in 2026 to facilitate a transition to the Proteus platform[9] Shareholder Information - The company reported a weighted-average share count of 209,185 million for Q4 2025, up from 146,239 million in Q4 2024, affecting per-share loss calculations[27] Other Financial Metrics - Interest income for the year ended December 31, 2025, was $8,964 million, slightly down from $9,638 million in 2024[24] - The company experienced a change in fair value of warrant liabilities, resulting in a gain of $4,202 million for the year ended December 31, 2025[27]

Quantum-Si Conference Call Summary Company Overview - **Company**: Quantum-Si (NasdaqGM:QSI) - **Industry**: Life Sciences Tools and Diagnostics - **Technology**: Utilizes semiconductor chip technology for single-molecule protein sequencing with products including the Platinum instrument and QSI Cloud software [3][4] Key Points and Arguments Product Portfolio and Technology - **Current Products**: The first-generation technology includes the Platinum and Platinum Pro instruments, which have been in the market for about three years [4] - **Business Model**: Operates on a razor-razor blade model where customers purchase the machine and consumables for sample preparation and sequencing [4] - **Upcoming Product**: The Proteus platform represents a significant architectural change, moving optics from consumables to the machine, allowing for higher sequencing output and lower-cost consumables [5][15] Financial Performance and Strategy - **Recent Earnings**: The company has adapted to NIH headwinds by offering alternative purchasing options for the Platinum machine, resulting in 12 machines sold under this program, with over half going to academia [6] - **Publications**: Five publications have been released this year, indicating a strong pipeline and market development [6] - **Cash Position**: Ended Q3 2025 with over $230 million in cash, providing a runway into Q2 2028, which includes 18 months post-Proteus launch [44][46] Proteus Development and Launch Timeline - **Milestones**: Completed sequencing on over 50 runs of the Proteus prototype, achieving this milestone ahead of schedule [7][8] - **Launch Timeline**: Expected to launch Proteus by the end of 2026 [21][22] - **Early Access Program**: Targeting big centers with core labs for testing and comparison against existing technologies [26][28] Pricing Strategy - **Price Range**: Anticipated pricing for Proteus is between $300,000 and $500,000, reflecting its advanced capabilities compared to the current Platinum device priced at $125,000 [23][24] - **Market Accessibility**: The pricing strategy aims to balance value capture with accessibility to avoid constraining the number of potential users [25] R&D and Technological Advancements - **AI and Binding Kinetics**: The integration of AI tools has accelerated the development of engineered protein recognizers, enhancing the ability to achieve full proteome coverage [30][31] - **Proteome Coverage Goals**: Aiming to demonstrate coverage of all 20 amino acids by 2026, which would enable advanced applications in single amino acid variants and post-translational modifications (PTMs) [33] Commercialization Strategy - **Sales Strategy**: Considering various sales models for Proteus, including trade-ins for existing Platinum users, while leaning towards capital sales [39][40] - **Long-term Focus**: Emphasis on capital efficiency and targeted investments to support the Proteus launch and subsequent commercialization efforts [46][47] Additional Important Insights - **Engineering and Chemistry Hurdles**: Early data from Proteus shows improvements across all metrics compared to the Platinum machine, indicating a de-risked program moving towards commercialization [10][12] - **Controlled Cleavage Technology**: Future versions of Proteus may incorporate controlled cleavage technology to enhance sequencing capabilities [41][43] - **Strategic Opportunities**: Open to exploring strategic opportunities and technologies that align with Quantum-Si's goals, while maintaining focus on the Proteus launch [47]

Core Insights - The presentation aims to provide an overview of the company's advancements in proteomics and the associated challenges in understanding the complexity of the proteome [1] - The focus is on the Proteus program, which represents the majority of the company's R&D investment, highlighting its significance in enhancing performance [1] Group 1: Technology and R&D - The company is investing heavily in the Proteus program, which is central to its current R&D efforts [1] - There are also modest investments in long-term technology development, indicating a balanced approach to immediate and future innovations [1] Group 2: Future Developments - Upcoming discussions will include plans to expand to 20 amino acids, with details on the timeline for achieving this goal [2]